Aclaris Therapeutics (ACRS) News Today → Better than Bitcoin? The Biotech Stock with 46,751% Potential (From Behind the Markets) (Ad) Free ACRS Stock Alerts $1.20 +0.01 (+0.84%) (As of 04/26/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineAclaris Therapeutics Incmoney.usnews.com - April 27 at 8:10 AMBML Capital Management LLC Invests $686,000 in Aclaris Therapeutics, Inc. (NASDAQ:ACRS)marketbeat.com - April 24 at 5:18 AMFavourable Signals For Aclaris Therapeutics: Numerous Insiders Acquired Stockfinance.yahoo.com - April 11 at 12:34 PMAclaris Therapeutics (NASDAQ:ACRS) Stock Rating Upgraded by StockNews.commarketbeat.com - March 25 at 11:46 PMACRS Apr 2024 1.000 callfinance.yahoo.com - March 16 at 7:45 PMAclaris Therapeutics (NASDAQ:ACRS) Lowered to "Sell" at StockNews.commarketbeat.com - March 8 at 2:14 AMHC Wainwright Analysts Reduce Earnings Estimates for Aclaris Therapeutics, Inc. (NASDAQ:ACRS)marketbeat.com - March 7 at 7:22 AMHC Wainwright Weighs in on Aclaris Therapeutics, Inc.'s FY2025 Earnings (NASDAQ:ACRS)marketbeat.com - March 6 at 8:32 AMAclaris Therapeutics: Cautious Hold Rating Amid Financial Stability and Pipeline Potentialmarkets.businessinsider.com - March 4 at 5:54 PMAclaris Therapeutics, Inc. (NASDAQ:ACRS) Short Interest Updatemarketbeat.com - March 4 at 11:57 AMAclaris Therapeutics: Hold Rating Amidst Strategic Review and Clinical Setbacksmarkets.businessinsider.com - March 1 at 10:55 AMAclaris Therapeutics, Inc. Forecasted to Earn Q1 2024 Earnings of ($0.31) Per Share (NASDAQ:ACRS)marketbeat.com - March 1 at 7:45 AMDeutsche Bank AG Sells 932,311 Shares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS)marketbeat.com - March 1 at 4:35 AMResearch Analysts Issue Forecasts for Aclaris Therapeutics, Inc.'s Q1 2025 Earnings (NASDAQ:ACRS)marketbeat.com - February 29 at 8:53 AMAnalysts Have Just Cut Their Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Revenue Estimates By 51%finance.yahoo.com - February 29 at 8:20 AMAclaris Therapeutics GAAP EPS of -$0.02 beats by $0.31, revenue of $17.6M beats by $12.55Mmsn.com - February 27 at 10:34 AMAclaris Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Updateglobenewswire.com - February 27 at 7:00 AMPacira (PCRX) Earnings Expected to Grow: What to Know Ahead of Q4 Releasefinance.yahoo.com - February 20 at 3:59 PMAclaris Therapeutics (ACRS) Scheduled to Post Earnings on Wednesdaymarketbeat.com - February 20 at 7:32 AMWill Aclaris Therapeutics (ACRS) Report Negative Q4 Earnings? What You Should Knowfinance.yahoo.com - February 15 at 1:52 PMAclaris Therapeutics, Inc. (NASDAQ:ACRS) to Post FY2023 Earnings of ($1.63) Per Share, Leerink Partnrs Forecastsmarketbeat.com - February 7 at 8:02 AMAclaris Therapeutics Executive Team Undergoes Major Changesmsn.com - February 6 at 9:54 AMAnalysts Set Expectations for Aclaris Therapeutics, Inc.'s Q3 2024 Earnings (NASDAQ:ACRS)marketbeat.com - February 6 at 7:47 AMHW Wainwright cuts Aclaris to neutral, cites underwhelming study datamsn.com - January 22 at 7:33 PMWhy Is Dermatology Focused Aclaris Therapeutics Stock Trading Higher Today?msn.com - January 16 at 10:48 PMAclaris moves on from CEO and begins strategic review following recent setbacksbizjournals.com - January 16 at 12:47 PMBTIG Downgrades Aclaris Therapeutics (ACRS)msn.com - January 11 at 7:57 PMThe Analyst Landscape: 4 Takes On Aclaris Therapeuticsmarkets.businessinsider.com - January 11 at 2:56 PMJefferies gets more bearish on Aclaris Therapeutics, downgrades sharesrealmoney.thestreet.com - January 11 at 9:56 AMAclaris downgraded at Jefferies despite mid-stage win for eczema therapymsn.com - January 10 at 6:39 PMAnalyst Highlights Aclaris Therapeutics' Encouraging Efficacy For Eczema Candidate, But Cautions On Data Variationsmarkets.businessinsider.com - January 10 at 6:39 PMAclaris Therapeutics Shares Fall On Mixed Results From Mid-Stage Eczema Trialmsn.com - January 10 at 1:39 PMAclaris Therapeutics Shares Down 12% Following Top-Line Results for Atopic Dermatitis Treatmentmarketwatch.com - January 10 at 7:43 AMAclaris Therapeutics Reports Positive Top-line Results From Phase 2b ATI-1777-AD-202 Studymarkets.businessinsider.com - January 10 at 7:43 AMAclaris Therapeutics Announces Top-line Results from 4-Week Phase 2b Trial of ATI-1777 for Mild to Severe Atopic Dermatitisfinance.yahoo.com - January 10 at 7:43 AMAre Medical Stocks Lagging Aclaris Therapeutics (ACRS) This Year?msn.com - January 4 at 12:00 PMAnalysts Offer Insights on Healthcare Companies: GoodRx Holdings (GDRX), Aclaris Therapeutics (ACRS) and Ocular Therapeutix (OCUL)markets.businessinsider.com - January 2 at 10:58 PMBuy Rating Justified by Aclaris Therapeutics’ Strategic Focus and Robust Financial Managementmarkets.businessinsider.com - December 30 at 10:16 AMMain Line biopharmaceutical firm to cut workforce by nearly halfbizjournals.com - December 20 at 5:48 PMInflammatory Disease Focused Aclaris Therapeutics Reduces Staff After Failed Psoriatic Arthritis Studymsn.com - December 20 at 12:48 PMAclaris Therapeutics, Inc.: Aclaris Therapeutics Provides Corporate Updatefinanznachrichten.de - December 20 at 7:47 AMAclaris Therapeutics to Reduce Workforce by Nearly Halfmarketwatch.com - December 19 at 5:49 PMAclaris to slash 46% of workforce as it reprioritizes drug programsmsn.com - December 19 at 5:49 PMAclaris Therapeutics Provides Corporate Updatefinance.yahoo.com - December 19 at 5:49 PMBreaking Down Aclaris Therapeutics: 6 Analysts Share Their Viewsmarkets.businessinsider.com - December 18 at 8:34 PMAclaris Therapeutics Stock: A Deep Dive Into Analyst Perspectives (6 Ratings)markets.businessinsider.com - December 18 at 3:34 PMAclaris Therapeutics: Buy Rating Justified by Strategic Partnerships and Strong Clinical Pipeline Potentialmarkets.businessinsider.com - December 8 at 10:37 PMLab Notes: Pavella gets $5M payday from expanded partnership; Aclaris enters licensing dealbizjournals.com - December 8 at 12:36 PMSun Pharma subsidiary partners with Aclaris Therapeutics for licensing agreementmsn.com - December 6 at 2:57 AMAclaris Therapeutics Announces Patent License Agreement with Sun Pharma for Alopeciafinance.yahoo.com - December 5 at 8:17 PM Get Aclaris Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ACRS and its competitors with MarketBeat's FREE daily newsletter. Email Address Forget AI, Imperium Is Expected to Grow 320,00% in 3 Years (Ad)If you think AI is big, then you have got to check out something I call Imperium… By my calculations, it’s set to grow 320,000% in three years. (You can see my calculations here.) Watch my video for all of the details ACRS Media Mentions By Week ACRS Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ACRS News Sentiment▼1.670.32▲Average Medical News Sentiment ACRS News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ACRS Articles This Week▼12▲ACRS Articles Average Week Get Aclaris Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ACRS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Clearside Biomedical News Today DiaMedica Therapeutics News Today PMV Pharmaceuticals News Today Chimerix News Today BioXcel Therapeutics News Today Eton Pharmaceuticals News Today Oncolytics Biotech News Today Affimed News Today Allakos News Today Hookipa Pharma News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ACRS) was last updated on 4/27/2024 by MarketBeat.com Staff From Our PartnersThese AI trades triggered this morning (545% return)Prosper Trading AcademyConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithThe World's First "$20 Trillion Drug?"Behind the MarketsFed launches fourth dollar overhaulStansberry ResearchBiden out June 13; Kamala won’t replace him?Paradigm PressJeff Bezos Just Humiliated Elon MuskInvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aclaris Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
